CoChat
Sign Up
Cited by 188Blood Pressure and Hypertension StudiesPeripheral Artery Disease ManagementCardiovascular Health and Disease Prevention

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease: Findings From the INternational VErapamil-SR/Trandolapril STudy

Open access
Bavry, Anthony A., Anderson, R. David, Gong, Yan, Denardo, Scott J., Cooper-DeHoff, Rhonda M., Handberg, Eileen M., Pepine, Carl J.·2010·Hypertension
DOI 10.1161/hypertensionaha.109.142240PMC PMC3000120
Open this paper in CoChat — free account

Abstract

Hypertension is a common risk factor for peripheral arterial disease (PAD). Guidelines suggest treating PAD patients to a blood pressure <130/80 mm Hg; therefore, our objective was to explore whether attainment of this target blood pressure is associated with improved outcomes. We performed a post hoc analysis of the INternational VErapamil-SR/Trandolapril STudy, a randomized clinical trial, which included hypertensive patients with concomitant PAD and coronary artery disease. There were 2699 PAD patients followed for a mean of 2.7 years (60 970 patient-years). The primary outcome, all-cause death, nonfatal myocardial infarction, or nonfatal stroke, occurred in 16.3% of PAD patients versus 9.2% without PAD (adjusted hazard ratio: 1.26 [95% CI: 1.13 to 1.40]; P <0.0001). The primary outcome occurred least frequently among PAD patients treated to an average systolic blood pressure of 135 to 145 mm Hg and an average diastolic blood pressure of 60 to 90 mm Hg. PAD patients displayed a J-shape relationship with systolic blood pressure and the primary outcome, although individuals without PAD did not. PAD patients may require a different target blood pressure than those without PAD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/hypertensionaha.109.142240

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. 10.1001/jama.1991.03460040065031 · DOI

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Bavry, A. A., Anderson, R. D., Gong, Y., Denardo, S. J., Cooper-DeHoff, R. M., Handberg, E. M., & Pepine, C. J.
Affiliations
  • University of Florida (US)
  • From the Division of Cardiovascular Medicine, College of Medicine (A.A.B., R.D.A., S.J.D., R.M.C.-D., E.M.H., C.J.P.), and Department of Pharmacotherapy and Translational Research, College of Pharmacy (Y.G., R.M.C.-D.), University of Florida, Gainesville, Fla.
ORCID
Venue
Hypertension
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2010-01
Volume
55
Issue
1
Pages
48-53
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
DOI
10.1161/hypertensionaha.109.142240
PMC
PMC3000120
OpenAlex
W2019678113
Semantic Scholar
902882d2b6ece6b530f147192a35483f0cc6b00a
Cited by
188
References
31
Citations by year
2026: 7 · 2025: 5 · 2024: 15 · 2023: 16 · 2022: 10 · 2021: 22 · 2020: 14 · 2019: 15 · 2018: 16 · 2017: 15 · 2016: 7 · 2015: 2 · 2014: 5 · 2013: 7 · 2012: 10
FWCI
6.90
Type
journal article
Language
en
Open access
Locations
  • Hypertension (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Heart, Lung, and Blood Institute (K23HL086558)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
peripheral arterial disease, coronary artery disease, blood pressure targets, systolic blood pressure, J-shaped relationship, cardiovascular outcomes, all-cause mortality, myocardial infarction, stroke, antihypertensive therapy
MeSH terms
Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Aspirin, Blood Pressure, Coronary Artery Disease, Female, Follow-Up Studies, Humans, Hypertension, Male, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Peripheral Vascular Diseases, Outcome Assessment, Health Care, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review